In this issue:
Neoadjuvant intensity-modulated RT for centrally located HCC
TACE and SBRT then immunotherapy for locally advanced, unresectable HCC
Robotic vs. open liver resection for HCC
Same-stay work-up and procedure SIRT in unresectable liver tumours
Atezolizumab + bevacizumab vs. lenvatinib or sorafenib in nonviral unresectable HCC
Lenvatinib + TACE as first-line treatment for advanced HCC
Predicting MVI preoperatively for HCC scheduled for curative surgery
Molecular markers of response to anti-PD1 therapy in advanced HCC
MAFLD-associated HCC trends
Mailed outreach strategy for HCC surveillance
Global burden of primary liver cancer: 2020–2040
Please login below to download this issue (PDF)